APC-80200 (Mylovenge) has been developed for the treatment of B-cell malignancies and is currently in phase II clinical trials as a therapeutic vaccine for patients with advanced multiple myeloma. This vaccine candidate appears to be of particular benefit in patients who have received high-dose chemotherapy to reduce tumor load following stem cell rescue. APC-80200 is also being tested in patients with amyloidosis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
technology evaluation
4
evaluation apc-80200
4
apc-80200 dendreon
4
dendreon apc-80200
4
apc-80200 mylovenge
4
mylovenge developed
4
developed treatment
4
treatment b-cell
4
b-cell malignancies
4
malignancies currently
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!